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Introduction
Cerebral infarction (CI) accounts for 70-80% of all strokes in 
Japan.
1 Predicting the outcome after an acute CI is important 
for both clinicians and patients; however, such predictions 
remain difficult. Many factors are associated with the poor 
outcome of patients with acute CI, including gender, age, 
congestive heart failure, dementia, stroke severity, and dia-
betes mellitus.
2-4 Although many studies have indicated that 
the outcome after an acute CI is worse among women than 
among men,
5-11 some other studies found no such difference.
3,12
Several studies have investigated the relationship between 
levels of plasma hemostatic markers and acute CI subtypes. 
D-dimer is a marker of the fibrinolytic state, and the level of 
this marker is typically higher in cases with cardioembolism 
than in cases with other CI subtypes (i.e., atherothrombosis 
and lacunar infarction). We previously reported that an ele-
vated D-dimer level was useful for distinguishing cardioem-
bolic infarction from other CI subtypes in the emergency 
room.
13 Some investigators have reported that the D-dimer 
level is an independent predictor of poor outcome among pa-
tients with acute CI.
14-16 However, conflicting results have 
also been reported.
17-20 Therefore, in the present study we ret-
rospectively investigated whether the D-dimer level upon 
admission and other clinical characteristics could be used to 
predict the poor outcome of patients with acute CI.
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Methods
Study subjects
Consecutive patients with acute CI who were admitted to our 
university hospital between January 1, 2002, and December 
31, 2006, were used as the study group. The following inclu-
sion criteria were applied:
1) Neurological signs including paralysis, agnosia, aprax-
ia, sensory disturbance, and cortical signs.
2) Lack of intracerebral hemorrhage, subarachnoid hemor-
rhage, and mass lesions on computed tomography (CT) or 
magnetic resonance imaging (MRI).
3) Admission within 24 hours after the onset of neurologic 
symptoms.
4) Determination of D-dimer levels within 3 days after ad-
mission.
Patients were excluded if they met one of the following 
criteria: epilepsy, systemic inflammatory or infectious dis-
eases, the presence of diseases of the central nervous system 
other than CI on subsequent CT or MRI findings, or head in-
jury. This retrospective study was performed in accordance 
with the Declaration of Helsinki.
Clinical characteristics
The presence of risk factors and co morbidities affecting 
thromboembolic events was determined. These factors in-
cluded age, gender, hypertension, diabetes mellitus, conges-
tive heart failure, underlying organic heart diseases, atrial fi-
brillation, and a prior history of CI or transient ischemic 
attack (TIA). The CHADS2 (congestive heart failure, hyper-
tension, age ≥75 years, diabetes mellitus, prior stroke or 
TIA) score was calculated to determine the levels of cardio-
embolic risk as follows:
21 1 point was given for the presence 
of each of advanced age (75 years or older), hypertension, 
congestive heart failure, and diabetes mellitus; while 2 points 
were given for the presence of a prior CI or TIA. The use of 
antithrombotic drugs, including warfarin and antiplatelet 
drugs, was also determined. For patients with repeated ad-
mission as a result of CI during the enrollment period, only 
the first admission was included in the present analyses.
Subtypes of cerebral infarction
The CI cases were classified into the following five groups 
using the Trial of Org 10172 in Acute Stroke Treatment cri-
teria for acute CI
22 and subsequent MRI and magnetic reso-
nance angiography findings: cardioembolic diseases, large-
artery atherothrombosis (atherothrombosis), small-vessel 
occlusion (lacunar infarction), unknown cause, and other 
(e.g., dissection of the cerebral artery or coagulation abnor-
malities). When two potential sources of CI were present 
concomitantly, such as cardiac embolism and large-artery 
atherothrombosis, the CI subtype was defined as “unknown 
cause”. Two neurologists who were unaware of the progno-
sis confirmed the final diagnosis of the CI subtype.
Outcome
Outcome was determined using the score on the modified 
Rankin scale (mRS; 0-6) at 30 days after hospitalization,
23 
with an mRS score of 3-6 defined as a poor outcome.
24,25
Statistical analyses
Continuous variables are shown as mean±SD values, while 
categorical variables are shown as percentages. A chi-square 
test was used to compare categorical variables, while an un-
paired t-test was used to compare continuous variables. A 
multivariate analysis was performed using the Cox propor-
tional-hazards regression analysis to determine independent 
predictors of poor outcome. Explanatory variables were se-
lected from the clinical characteristics that differed signifi-
cantly between patients with a poor outcome and the remain-
ing subjects. The data were analyzed using StatView, version 
J5.0 (SAS Institute, Berkeley, CA, USA). The level of statis-
tical significance was set at p<0.05.
Results
The study cohort comprised 359 patients (129 women and 
230 men) aged 71.8±11.7 years. The clinical characteristics 
are compared between the men and women in Table 1. Ex-
cept for age, no significant differences were noted in the 
clinical characteristics between the genders, including the 
CHADS2 score and antithrombotic drug usage. The distribu-
tion of the Trial of Org 10172 in Acute Stroke Treatment 
classification differed significantly between the men and wo-
men (p=0.04), with women being less likely to have large-ar-
tery atherothrombosis (24.8% vs. 37.4%) but more likely to 
have cardioembolism (39.5% vs. 25.7%)(Table 1). Three pa-
tients received intravenous tissue plasminogen activator (t-
PA) treatment during the acute phase of CI after blood sam-
ples were obtained for the determination of D-dimer levels; 
these three patients were included in the subsequent analyses.
The plasma D-dimer level was determined in the emer-
gency room on admission (day 1) in most of the patients (322 
patients, 89.7%), on day 2 in 20 patients, and on day 3 in 17 
patients. The D-dimer level tended to be higher among the 
women than among the men (p=0.05).
Outcome
The hospitalization period ranged from 2 to 216 days (medi-
an, 24 days). Seventeen patients (4.7%) died (mRS score=6) Dougu N et al.
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and 70 patients (19.5%) were bedridden (mRS score=5) at 
30 days after hospitalization. The mean mRS score was sig-
nificantly higher among the women than among the men 
(p<0.01). Consequently, a poor outcome (mRS score ≥3) 
was observed more frequently among the women than 
among the men (p<0.01)(Table 1).
Risk factors of poor outcome
Table 2 compares the clinical characteristics and warfarin us-
age between patients with poor and good outcomes. The 
prevalences of female gender, cardioembolism, advanced 
age (≥75 years), prior history of CI or TIA, and elevated D-
dimer level (≥1.0 μg/mL) were significantly higher among 
patients with a poor outcome (Table 2). The results of a mul-
tivariate analysis are summarized in Table 3. Elevated D-di-
mer level (≥1.0 μg/mL), advanced age, and female gender 
were independent predictors of poor outcome.
The predictive values of various combinations of indepen-
dent predictors are summarized in Table 4. When all three 
predictors were combined, the negative predictive value was 
quite high but the positive predictive value was relatively 
low. Combining at least two predictors yielded modest posi-
tive and negative predictive values.
Discussion
Major findings
There are three major findings of the present study. First, 
compared with the men, the women with acute CI were old-
er, suffered more frequently from cardioembolism and less 
frequently from atherothrombosis, and had a worse outcome 
at 30 days after hospitalization. Second, in a multivariate 
analysis, female gender, advanced age (≥75 years), and ele-
vated D-dimer level (≥1.0 μg/mL) were independent predic-
tors of a poor outcome (mRS score ≥3). Finally, combining 
at least two of these predictors yielded modest positive and 
negative predictive values.
Predictors of outcome among patients  
with acute CI
Many clinical characteristics are known to be predictors of a 
poor outcome among patients suffering acute CI,
2-4 including 
age, gender, severity of CI, cardiovascular comorbidities, di-
abetes mellitus, and prestroke functional status. Some blood 
markers are also associated with a poor outcome among patients 
with CI.
18,26 Higher levels of C-reactive protein,
15,18,19 D-di-
mer,
14-16 plasminogen activator inhibitor-1,
20 and fibrinogen
19 
have been reported to predict a poor outcome; however, the 
previous results have not always been consistent.
17 In the 
present study, advanced age (≥75 years), a female gender, 
and an elevated D-dimer level were independent predictors 
of a poor outcome (mRS score ≥3). These findings are con-
sistent with those of several previous studies.
2,14-16 Important-
ly, combining all three predictors yielded a high negative 
predictive value (0.889).
Female gender as a predictor of poor outcome
Whether being female is an independent predictor of a poor 
outcome among patients with acute CI remains controver-
sial. The Framingham Heart Study, Rotterdam Study, and 
European BIOMED Study found that the mortality rate did 
not differ between men and women who had suffered a st-
roke.
3,12,27 However, the World Health Organization’s MONI-
CA (Multinational MONItoring of trends and determinants 
in CArdiovascular disease) study and the International Stro-
ke Trial revealed that the mortality rate was significantly hig-
her among women than among men.
28 Many other studies ha-
ve indicated that the outcome after acute stroke is worse am-
ong women than among men.
5-11 In Japan, Fukuda et al.
11 re-
ported the long-term outcome of patients with CI. Only age 
and female gender were found to be independent predictors 
of poor locomotive function. The mortality rate was also hig-
her among the women than among the men.
11 The etiology of 
the poor functional outcome seen in women is likely to be mul-
tifactorial. A more advanced age,
3,29,30 more risk factors,
3,29,31 a 
higher prevalence of cardioembolism,
29,31 a greater severity 
of CI upon admission,
29 and a weaker muscular strength
32 are 
observed more frequently among women than among men 
who suffer from stroke. In the present study, we also found 
that the women were older and suffered from cardioembo-
lism more frequently than the men. However, the severity of 
CI, muscle strength, and prestroke functional conditions we-
re not determined in the present study. 
D-dimer levels and poor prognosis
D-dimer levels are an index of fibrinolysis, and elevated val-
ues are associated with thrombogenesis in the cardiovascular 
system. Among the three subtypes of acute CI, cardioembo-
lism is generally associated with the highest D-dimer lev-
el.
33,34 The determination of D-dimer levels in patients with 
acute CI could provide valuable prognostic information. 
Feinberg et al.
35 reported that the D-dimer level was signifi-
cantly higher among patients with cardioembolism than 
among those with other CI subtypes, and that it was a predic-
tor of mortality. Montaner et al.
36 showed that a combination 
of high levels of brain natriuretic peptide and D-dimer could 
identify cardioembolic stroke in the acute phase. Berge et 
al.
37 showed that higher D-dimer levels were related to stroke 
severity on admission and a worse outcome. However, other 
investigators found no such correlations between D-dimer Predictors of Poor Outcome of Cerebral Infarction
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levels and stroke severity and mortality.
17,38 Plasminogen ac-
tivator inhibitor-1,
20 fibrinopeptide A,
35 and fibrinogen
19 have 
also been reported as independent predictors of outcome af-
ter acute CI. Furthermore, an elevated C-reactive protein 
level was found to be an independent predictor of poor out-
come after acute CI.
15,18,19
In the present study, the D-dimer level - which was the 
only hemostatic marker determined upon admission - was an 
independent predictor of a poor outcome determined at 30 
days after hospitalization. This finding could reflect a corre-
Table 1. Clinical characteristics of the patients, stratified according to gender
Men (n=230) Women (n=129) p
Age (years) 69.6±11.4 75.8±11.1 <0.01
Underlying diseases
Hypertension 116 (50.4) 69 (53.5) 0.63
Diabetes mellitus 56 (24.3) 23 (17.8) 0.15
Congestive heart failure 12 (5.2) 8 (6.2) 0.70
Organic heart diseases 43 (18.7) 26 (20.2) 0.73
Atrial fibrillation 66 (28.7) 46 (35.7) 0.14
Prior cerebral infarction/TIA 46 (20.0) 16 (12.4) 0.07
CHADS2 score 1.6±1.2 1.7±1.1 0.64
Antithrombotic medication
Warfarin 25 (9.8) 8 (6.2) 0.14
Antiplatelet drugs 52 (23.9) 25 (19.4) 0.48
Subtypes of cerebral infarction 0.04
Atherothrombotic 86 (37.4) 32 (24.8)
Cardioembolic 59 (25.7) 51 (39.5)
Lacunar 66 (28.7) 37 (28.7)
Unknown cause 13 (5.6) 5 (3.9)
Other 6 (2.6) 4 (3.1)
D-dimer (μg/mL) 1.93±3.63 2.78±4.65 0.05
mRS score
0-2 128 (55.7) 43 (38.0) <0.01
3-5 91 (39.5) 80 (62.0) <0.01
6 (death) 11 (4.8) 6 (4.7) 0.81
Mean 2.5±1.9 3.3±1.8 <0.01
Data are mean±SD values or the numbers (%) of patients.
TIA: transient ischemic attack, CHADS2: congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or TIA, 
mRS: modified Rankin scale.
Table 2. Univariate analyses of variables associated with outcome at 30 days after hospitalization
Outcome
p
Poor (n=179) Good (n=180)
Women 81 (45.3) 48 (26.7) <0.01
Cardioembolism 67 (37.4) 43 (23.9) <0.01
Congestive heart failure 13 (7.3) 7 (3.9) 0.16
Hypertension 88 (49.2) 98 (54.4) 0.32
Age ≥75 years 111 (63.1) 68 (37.8) <0.01
Diabetes mellitus 40 (22.3) 39 (21.7) 0.88
Prior cerebral infarction/TIA 38 (21.2) 24 (13.3) 0.05
Organic heart diseases 31 (17.3) 38 (21.1) 0.36
Warfarin 16 (8.9) 17 (9.4) 0.87
Antiplatelet drugs 39 (21.8) 38 (21.1) 0.88
Elevated D-dimer level (≥1.0 μg/mL) 126 (70.4) 74 (41.1) <0.01
Outcome was defined as poor when the score on the mRS was ≥3 and as good when the score was ≤2.
Values are the numbers (%) of patients.
mRS: modified Rankin scale, TIA: transient ischemic attack.Dougu N et al.
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lation between cardioembolism and an elevated D-dimer 
level. Cardioembolism is generally more severe and is asso-
ciated with a higher mortality rate and higher levels of D-di-
mer than other CI subtypes.
13,33,38 However, some investiga-
tors have reported conflicting data regarding the relationship 
between the D-dimer level and CI subtypes.
39,40 In the pres-
ent study, cardioembolism was not an independent predictor 
of a poor outcome (Table 3).
Systemic diseases, including malignancy and infection, are 
associated with elevated D-dimer levels; this observation 
might explain the relationship between an elevated D-dimer 
level and a poor outcome in the present study. However, only 
three patients had a concomitant malignancy, and patients 
with systemic inflammatory or infectious diseases were ex-
cluded from this study. Treatment with warfarin can decrease 
the D-dimer level, possibly modifying the present results. 
The severity of CI in patients receiving warfarin treatment 
might be less than that among those who are not receiving 
warfarin treatment.
41,42 However, warfarin usage on admis-
sion did not differ between patients with poor and good out-
comes.
Limitations
The present study was subject to several limitations. First, 
stroke severity (e.g., as assessed on the National Institutes of 
Health Stroke Scale) upon admission and functional status 
before admission were not determined in the present study, 
since the data were analyzed retrospectively. Second, the D-
dimer levels were not determined serially and were only de-
termined upon admission in approximately 90% of the pa-
tients. The serial determination of D-dimer levels might have 
modified the present results. Finally, thrombolytic therapy 
with t-PA was performed only in three patients. The D-dimer 
level increases significantly after fibrinolytic therapy.
43 Thus, 
the more widespread use of t-PA among our cohort may have 
influenced the obtained results.
Conclusion
Despite the aforementioned limitations, the present study has 
revealed that certain clinical characteristics - such as female 
gender, advanced age, and elevated D-dimer levels upon ad-
mission - may be used to predict the outcome after acute CI.
Conflicts of Interest
The authors have no financial conflicts of interest.
REFERENCES
1. Kitamura A, Iso H, Iida M, Naito Y, Sato S, Jacobs DR, et al. Trends 
in the incidence of coronary heart disease and stroke and the preva-
lence of cardiovascular risk factors among Japanese men from 1963 
to 1994. Am J Med 2002;112:104-109.
2. Appelros P, Nydevik I, Viitanen M. Poor outcome after first-ever 
stroke: predictors for death, dependency, and recurrent stroke within 
the first year. Stroke 2003;34:122-126.
3. Di Carlo A, Lamassa M, Baldereschi M, Pracucci G, Basile AM, 
Wolfe CD, et al. Sex differences in the clinical presentation, resource 
use, and 3-month outcome of acute stroke in Europe: data from a 
multicenter multinational hospital-based registry. Stroke 2003;34: 
1114-1119.
4. Howard G, Walker MD, Becker C, Coull B, Feibel J, McLeroy K, et 
al. Community Hospital-based Stroke Programs: North Carolina, Or-
egon, and New York. III. Factors influencing survival after stroke: 
proportional hazards analysis of 4219 patients. Stroke 1986;17:294-
299.
5. Turaj W, Slowik A, Wnuk M, Szczudlik A. Gender-related differenc-
es in diagnostic evaluation and outcome of ischemic stroke in Po-
land. Stroke 2009;40:980-982.
6. Lewsey JD, Gillies M, Jhund PS, Chalmers JW, Redpath A, Briggs A, 
et al. Sex differences in incidence, mortality, and survival in individu-
als with stroke in Scotland, 1986 to 2005. Stroke 2009;40:1038-1043.
7. Appelros P, Stegmayr B, Terént A. Sex differences in stroke epidemi-
ology: a systematic review. Stroke 2009;40:1082-1090.
8. Eriksson M, Glader EL, Norrving B, Terént A, Stegmayr B. Sex dif-
ferences in stroke care and outcome in the Swedish national quality 
register for stroke care. Stroke 2009;40:909-914.
9. Smith DB, Murphy P, Santos P, Phillips M, Wilde M. Gender differ-
ences in the Colorado Stroke Registry. Stroke 2009;40:1078-1081.
10. Reid JM, Dai D, Gubitz GJ, Kapral MK, Christian C, Phillips SJ. 
Table 3. Multivariate analysis for a poor outcome (mRS score ≥3) at 30 days after hospitalization
OR 95% CI p
Female gender 1.75 1.08-2.83 0.02
Cardioembolism 1.39 0.85-2.29 0.19
Age ≥75 years 1.93 1.21-3.07 <0.01
Prior cerebral infarction/TIA 1.70 0.94-3.11 0.08
Elevated D-dimer level (≥1.0 μg/mL) 2.45 1.52-3.89 <0.01
OR: odds ratio, 95% CI: 95% confidence interval, mRS: modified Rankin scale, TIA: transient ischemic attack.
Table 4. Efficacy of combining age ≥75 years, female gender, and elevated D-dimer level for predicting a poor outcome (mRS score ≥3)
Sensitivity Specificity PPV NPV
All three factors 0.688 0.542 0.246 0.889
At least two factors 0.672 0.664 0.653 0.683
At least one factor 0.585 0.770 0.889 0.372
PPV: positive predictive value, NPV: negative predictive value, mRS: modified Rankin scale.Predictors of Poor Outcome of Cerebral Infarction
202  J Clin Neurol 2011;7:197-202
Gender differences in stroke examined in a 10-year cohort of patients 
admitted to a Canadian teaching hospital. Stroke 2008;39:1090-1095.
11. Fukuda M, Kanda T, Kamide N, Akutsu T, Sakai F. Gender differ-
ences in long-term functional outcome after first-ever ischemic stro-
ke. Intern Med 2009;48:967-973.
12. Petrea RE, Beiser AS, Seshadri S, Kelly-Hayes M, Kase CS, Wolf 
PA. Gender differences in stroke incidence and poststroke disability 
in the Framingham heart study. Stroke 2009;40:1032-1037.
13. Dougu N, Takashima S, Sasahara E, Taguchi Y, Toyoda S, Hirai T, et 
al. Differential diagnosis of cerebral infarction using an algorithm 
combining atrial fibrillation and D-dimer level. Eur J Neurol 2008; 
15:295-300.
14. Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. D-dimer 
predicts early clinical progression in ischemic stroke: confirmation 
using routine clinical assays. Stroke 2006;37:1113-1115.
15. Welsh P, Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. 
Associations of inflammatory and haemostatic biomarkers with poor 
outcome in acute ischaemic stroke. Cerebrovasc Dis 2009;27:247-
253.
16. Tombul T, Atbas C, Anlar O. Hemostatic markers and platelet aggre-
gation factors as predictive markers for type of stroke and neurologi-
cal disability following cerebral infarction. J Clin Neurosci 2005;12: 
429-434.
17. Squizzato A, Ageno W, Finazzi S, Mera V, Romualdi E, Bossi A, et 
al. D-dimer is not a long-term prognostic marker following acute ce-
rebral ischemia. Blood Coagul Fibrinolysis 2006;17:303-306.
18. Di Napoli M, Papa F; Villa Pini Stroke Data Bank Investigators. In-
flammation, hemostatic markers, and antithrombotic agents in rela-
tion to long-term risk of new cardiovascular events in first-ever isch-
emic stroke patients. Stroke 2002;33:1763-1771.
19. Rallidis LS, Vikelis M, Panagiotakos DB, Liakos GK, Krania E, 
Kremastinos DT. Usefulness of inflammatory and haemostatic mark-
ers to predict short-term risk for death in middle-aged ischaemic 
stroke patients. Acta Neurol Scand 2008;117:415-420.
20. Lip GY, Blann AD, Farooqi IS, Zarifis J, Sagar G, Beevers DG. Se-
quential alterations in haemorheology, endothelial dysfunction, plate-
let activation and thrombogenesis in relation to prognosis following 
acute stroke: The West Birmingham Stroke Project. Blood Coagul 
Fibrinolysis 2002;13:339-347.
21. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Rad-
ford MJ. Validation of clinical classification schemes for predicting 
stroke: results from the National Registry of Atrial Fibrillation. 
JAMA 2001;285:2864-2870.
22. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon 
DL, et al. Classification of subtype of acute ischemic stroke. Defini-
tions for use in a multicenter clinical trial. TOAST. Trial of Org 
10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
23. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. 
Interobserver agreement for the assessment of handicap in stroke pa-
tients. Stroke 1988;19:604-607.
24. Jüttler E, Schweickert S, Ringleb PA, Huttner HB, Köhrmann M, As-
choff A. Long-term outcome after surgical treatment for space-occu-
pying cerebellar infarction: experience in 56 patients. Stroke 2009; 
40:3060-3066.
25. Ueda T, Sakaki S, Kumon Y, Ohta S. Multivariable analysis of pre-
dictive factors related to outcome at 6 months after intra-arterial 
thrombolysis for acute ischemic stroke. Stroke 1999;30:2360-2365.
26. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers 
for the prognosis of ischemic stroke: a systematic review. Stroke 2009; 
40:e380-e389.
27. Herman B, Leyten AC, van Luijk JH, Frenken CW, Op de Coul AA, 
Schulte BP. Epidemiology of stroke in Tilburg, the Netherlands. The 
population-based stroke incidence register: 2. Incidence, initial clini-
cal picture and medical care, and three-week case fatality. Stroke 
1982;13:629-634.
28. Brønnum-Hansen H, Davidsen M, Thorvaldsen P; Danish MONICA 
Study Group. Long-term survival and causes of death after stroke. 
Stroke 2001;32:2131-2136.
29. Roquer J, Campello AR, Gomis M. Sex differences in first-ever acute 
stroke. Stroke 2003;34:1581-1585.
30. Glader EL, Stegmayr B, Norrving B, Terént A, Hulter-Asberg K, 
Wester PO, et al. Sex differences in management and outcome after 
stroke: a Swedish national perspective. Stroke 2003;34:1970-1975.
31. Gray LJ, Sprigg N, Bath PM, Boysen G, De Deyn PP, Leys D, et al. 
Sex differences in quality of life in stroke survivors: data from the 
Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). Stroke 2007;38: 
2960-2964.
32. Paolucci S, Bragoni M, Coiro P, De Angelis D, Fusco FR, Morelli D, 
et al. Is sex a prognostic factor in stroke rehabilitation? A matched com-
parison. Stroke 2006;37:2989-2994.
33. Takano K, Yamaguchi T, Uchida K. Markers of a hypercoagulable 
state following acute ischemic stroke. Stroke 1992;23:194-198.
34. Kataoka S, Hirose G, Hori A, Shirakawa T, Saigan T. Activation of 
thrombosis and fibrinolysis following brain infarction. J Neurol Sci 
2000;181:82-88.
35. Feinberg WM, Erickson LP, Bruck D, Kittelson J. Hemostatic mark-
ers in acute ischemic stroke. Association with stroke type, severity, 
and outcome. Stroke 1996;27:1296-1300.
36. Montaner J, Perea-Gainza M, Delgado P, Ribó M, Chacón P, Rosell 
A, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma 
biomarkers. Stroke 2008;39:2280-2287.
37. Berge E, Friis P, Sandset PM. Hemostatic activation in acute isch-
emic stroke. Thromb Res 2001;101:13-21.
38. Ageno W, Finazzi S, Steidl L, Biotti MG, Mera V, Melzi D’Eril G, et 
al. Plasma measurement of D-dimer levels for the early diagnosis of 
ischemic stroke subtypes. Arch Intern Med 2002;162:2589-2593.
39. Fisher M, Francis R. Altered coagulation in cerebral ischemia. Plate-
let, thrombin, and plasmin activity. Arch Neurol 1990;47:1075-1079.
40. Tohgi H, Kawashima M, Tamura K, Suzuki H. Coagulation-fibrino-
lysis abnormalities in acute and chronic phases of cerebral thrombo-
sis and embolism. Stroke 1990;21:1663-1667.
41. Ay H, Arsava EM, Gungor L, Greer D, Singhal AB, Furie KL, et al. 
Admission international normalized ratio and acute infarct volume in 
ischemic stroke. Ann Neurol 2008;64:499-506.
42. Wakita M, Yasaka M, Minematsu K, Yamaguchi T. Effects of antico-
agulation on infarct size and clinical outcome in acute cardioembolic 
stroke. Angiology 2002;53:551-556.
43. Jin L, Jin H, Zhang G, Xu G. Changes in coagulation and tissue plas-
minogen activator after the treatment of cerebral infarction with lum-
brokinase. Clin Hemorheol Microcirc 2000;23:213-218.